Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.
Newly discovered mutation could explain aggressive prostate cancer in young men
Researchers at the University of British Columbia, BC Cancer, and international collaborators have identified inherited mutations in the cyclin-dependent kinase 12 (CDK12) gene as a rare but significant driver of aggressive hereditary prostate cancer, according to a study published in Cancer Discovery. Until now, CDK12 mutations in prostate cancer were thought to arise only spontaneously within tumor cells. The team, led by senior author Alexander Wyatt and lead author Sofie Tolmeijer, analyzed genetic data from more than 4,500 people with aggressive prostate cancer and identified five unrelated men with inherited CDK12 mutations, all of whom had developed metastatic disease between the ages of 44 and 62. Tumor analysis revealed a distinctive genetic fingerprint confirming CDK12 inactivation was driving disease. The mutation appears in roughly one in every 1,000 people with aggressive prostate cancer, but because inherited variants can be traced through family lines, identifying one carrier creates an opportunity to screen relatives before cancer develops. The researchers also flagged a potential link to ovarian cancer, with several patients reporting family histories of the disease. Crucially, existing clinical sequencing technology can already detect CDK12 mutations, meaning adding it to standard hereditary cancer panels could be relatively straightforward. – Andrea Corona
Satellos releases promising six-month interim data in Duchenne muscular dystrophy
On Wednesday, Satellos announced six-month interim data showing that its Duchenne muscular dystrophy (DMD) oral small molecule drug, SAT-3247, resulted in “reduced muscle fat fraction, increased total effort, stable strength, lower [creatine kinase], and a safety and tolerability profile consistent with previously reported data.” The drug works by inhibiting AAK1 (adaptor-associated kinase 1) and thus restoring the ability of muscle stem cells to divide. The data includes just four adults aged 21–28. “Although the study is small, the consistency across measures of strength, muscle composition, effort, quality of life and safety is highly encouraging for the ongoing clinical evaluation of SAT-3247 in TRAILHEAD and BASECAMP,” said Perry Shieh, Professor of Neurology and Pediatrics at the David Geffen School of Medicine at UCLA, in the press release. Satellos’ oral drug could be a welcome alternative to current options like the FDA-approved controversial gene therapy from Sarepta Therapeutics. – Allison Whitten
Veradermics shares surge as oral hair loss drug advances
Hair loss biotech Veradermics has emerged as one of the strongest biotech initial public offering performers of the year, with its shares rising more than 650 percent since its February market debut. The company initially raised $256.3 million before securing a further $472 million in follow-on financing. Its lead candidate VDPHL01 is an extended-release oral formulation of minoxidil being developed for male and female pattern hair loss. The therapy produced statistically significant improvements in hair growth over placebo in a Phase 2/3 trial involving more than 500 men, and Veradermics expects topline data from a confirmatory Phase 3 study later this year. If approved, VDPHL01 could become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years and the first oral therapy specifically approved for female pattern hair loss.The company is targeting a global pattern hair loss market projected to reach around $30 billion by 2028, where it will compete with established topical and oral treatments as well as emerging developers such as Pelage Pharmaceuticals, whose investigational candidate PP405 is also in clinical development for androgenetic alopecia. – Bree Foster
Ionis and AstraZeneca's heart drug misses its Phase 3 primary endpoint
Ionis Pharmaceuticals and AstraZeneca announced this week that CARDIO-TTRansform, the largest Phase 3 trial ever conducted in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), did not meet its primary endpoint. Eplontersen, a once-monthly RNA-targeted silencer that reduces production of the transthyretin (TTR) protein at its source in the liver, failed to show a statistically significant reduction in the composite of cardiovascular mortality and recurrent cardiovascular events versus placebo in 1,432 patients over 140 weeks. The likely culprit: The trial enrolled a contemporary patient population in which 57 percent were already on TTR stabilizers at baseline, and a further 24 percent initiated one during the trial. In patients on eplontersen monotherapy, a pre-specified subgroup analysis did show a nominally significant hazard ratio of 0.71, suggesting the drug may work but that its benefit is blunted when added on top of stabilizers. Multiple secondary imaging and biomarker endpoints favored eplontersen, and its safety profile was consistent with prior results. Full data will be presented at the European Society of Cardiology Congress in August 2026. The trial's outcome reflects a broader challenge in the ATTR-CM field: As the standard of care has improved rapidly, the bar for demonstrating additive benefit has risen with it. – Andrea Corona
Vertex expands rare disease pipeline with $10 billion Crinetics deal
Vertex Pharmaceuticals has agreed to acquire endocrine specialist Crinetics Pharmaceuticals for approximately $10 billion in its largest acquisition to date, expanding beyond its dominant cystic fibrosis franchise with a fifth therapeutic pillar focused on endocrine diseases. The deal adds the recently approved acromegaly treatment Palsonify, as well as atumelnant, an investigational drug being developed for congenital adrenal hyperplasia (CAH). In CAH, enzyme deficiencies block cortisol production, causing the body to overproduce the weak adrenal androgen androstenedione. In a Phase 2 trial, atumelnant produced rapid and sustained reductions of androstenedione of up to 80 percent within two weeks, alongside improvements in disease symptoms including menstrual function, adrenal enlargement, and androgen-related complications, with no treatment-related serious safety concerns reported. Vertex believes the acquisition will strengthen its rare disease pipeline as it seeks to diversify beyond cystic fibrosis, which generated the vast majority of the company's 2025 revenue, while analysts estimate Crinetics' two lead programs could together achieve peak annual sales of around $5 billion.– Bree Foster
FDA scrutinizes Lundbeck’s webpage claims in letter
In an untitled letter sent to Lundbeck, the FDA’s Office of Prescription Drug Promotion warned that several webpages describing Lundbeck’s intravenous migraine drug, Vyepti, are “false or misleading.” Specifically, the letter took issue with webpages on “Efficacy and 2-year patient outcomes” that stated the drug led 40 percent of patients to be 100 percent migraine free for a month or more. Citing data from the PROMISE-1 and PROMISE-2 trials that were post hoc analyses and thus only exploratory in nature, the letter states, “These claims and presentations create the misleading impression that patients treated with Vyepti will be 100% migraine-free for a month or more, when this has not been demonstrated.” Similarly, based on limitations from the REVIEW study, the agency wrote that the “Real VYEPTI experience” webpage “claims and presentations are presented in conjunction with attention-grabbing, colorful, bold graphics and charts with large font. These claims and presentations create a misleading impression.” The notice requested Lundbeck’s immediate action to address violations and respond within 15 working days. The letter continues a string of related notices from the FDA over the last few months to Pinnacle Biologics and QOL Medical. – Allison Whitten
